bath & body works holds annual meeting, elects board members

Bath & Body Works, Inc. (NYSE:BBWI) conducted its Annual Meeting of Stockholders today. The meeting, held in Columbus (WA:CLC), Ohio, focused on several key agenda items, including the election of directors, ratification of the accounting firm, and an advisory vote on executive compensation.

During the meeting, stockholders elected nine directors to the board for a one-year term. The elected directors are Alessandro Bogliolo, Lucy O. Brady, Francis A. Hondal, Danielle M. Lee, Sarah E. Nash, Juan Rajlin, Stephen D. Steinour, J.K. Symancyk, and Steven E. Voskuil. The voting results showed a strong majority support for each nominee, with the number of votes in favor significantly surpassing those against or abstaining. This governance stability comes as the company maintains impressive profitability metrics, with a gross profit margin of 44.6% and return on assets of 16.2%.

In addition to board elections, the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year 2025 was ratified. The proposal received 185,693,927 votes in favor, with 3,698,452 against and 241,948 abstentions.

The stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers. The proposal garnered 176,685,807 votes in favor, 2,201,152 votes against, and 317,521 abstentions. Notably, 98.77% of the shares voting on this proposal were in favor.

The meeting followed the resignation of Gina R. Boswell from the board on May 16, 2025, as previously announced. Votes cast for Ms. Boswell were disregarded.

This information is based on a press release statement from Bath & Body Works, Inc.

In other recent news, Bath & Body Works Inc. has garnered attention from several financial analysts following its first-quarter performance and future guidance. The company reported a 3% year-over-year increase in sales and earnings per share (EPS) of $0.49, with gross margins reaching 45.4%, surpassing expectations. Despite these positive results, the second-quarter guidance fell below consensus estimates, leading to some adjustments in analyst outlooks. Telsey Advisory Group reduced its price target from $43 to $38 while maintaining an Outperform rating, citing the company’s maintained full-year guidance as a positive sign amidst challenging conditions. Morgan Stanley also adjusted its price target from $43 to $41, keeping an Overweight rating but expressing concerns over the company’s tariff insulation and unclear full-year guidance.

Goldman Sachs reaffirmed its Buy rating with a price target of $43, highlighting Bath & Body Works’ strategic positioning and potential for growth through new product introductions and collaborations. UBS maintained a Neutral rating with a $36 target, noting long-term growth opportunities but expressing caution over the CEO transition and limited options to enhance margins. Raymond James confirmed an Outperform rating with a $37 target, emphasizing the company’s innovation and digital strategies under new leadership as promising factors for sustained growth. These recent developments reflect a mix of optimism and caution from analysts as Bath & Body Works navigates its strategic initiatives and market challenges.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.